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ABSTRACT Staphylococcus aureus is a human commensal but also has devastating
potential as an opportunistic pathogen. S. aureus bacteremia is often associated with
an adverse outcome. To identify potential targets for novel control approaches, we
have identiﬁed S. aureus components that are required for growth in human blood.
An ordered transposon mutant library was screened, and 9 genes involved speciﬁ-
cally in hemolysis or growth on human blood agar were identiﬁed by comparing the
mutants to the parental strain. Three genes (purA, purB, and pabA) were subse-
quently found to be required for pathogenesis in the zebraﬁsh embryo infection
model. The pabA growth defect was speciﬁc to the red blood cell component of hu-
man blood, showing no difference from the parental strain in growth in human se-
rum, human plasma, or sheep or horse blood. PabA is required in the tetrahydrofo-
late (THF) biosynthesis pathway. The pabA growth defect was found to be due to a
combination of loss of THF-dependent dTMP production by the ThyA enzyme and
increased demand for pyrimidines in human blood. Our work highlights pabA and
the pyrimidine salvage pathway as potential targets for novel therapeutics and sug-
gests a previously undeﬁned role for a human blood factor in the activity of sulfon-
amide antibiotics.
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The pathogenicity of the Gram-positive bacterium Staphylococcus aureus requires amultitude of virulence factors that are intricately coordinated and regulated (1, 2).
In addition to the more “classic” virulence factors, such as pore-forming toxins and
superantigens, fundamental metabolic processes of bacteria are also recognized as a
prerequisite for disease. Indeed, the majority of antibiotics act by disrupting essential
metabolic processes (3). However, pathogens, including S. aureus, have adapted so as
to resist such insults by switching off, or severely reducing, the activity of aspects of
metabolism in order to persist in the presence of antibiotics (4, 5).
Microbial ﬁtness during pathogenesis requires efﬁcient utilization of available nu-
trients. Although the mammalian host is nutrient rich, many nutrients are sequestered
as a means of inhibiting pathogen growth, a concept referred to as “nutritional
immunity” (6). Strategies for overcoming the nutrient-limited environment in vivo have
been well described for S. aureus and other bacteria; they include the upregulation of
peptide or amino acid transport mechanisms (7) and of proteins that enable the
acquisition of nutrients sequestered by the host (8, 9). De novo biosynthetic pathways
are also required to produce essential products not readily available in the environ-
ment. Nucleotide biosynthetic pathways have been identiﬁed as critical for the prolif-
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eration of Gram-positive pathogens on human blood (10), yet detailed studies of the
growth requirements of S. aureus are lacking.
To support studies on S. aureus, the Nebraska transposon mutant library (NTML) was
recently constructed in the community-acquired methicillin-resistant S. aureus (CA-
MRSA) USA300 JE2 strain, deposited in the Network on Antimicrobial Resistance in S.
aureus (NARSA) strain repository, and made freely available to registered users (11). This
library was created using the mariner-based transposon (bursa aurealis) and employing
the same methodology as that of Bae and colleagues (12). To date, the NTML has been
used to carry out diverse screens to identify genes involved in S. aureus antibiotic
persistence in vitro (13), altered hemolytic activity on rabbit blood agar (11, 14),
polymicrobial interactions (15), and hyaluronidase activity (16).
A comprehensive approach to identify genes involved in the growth of S. aureus on
human blood was undertaken using the NTML. The genes were then further charac-
terized to analyze their potential roles in human infection. We show that purine
biosynthesis is indispensable for growth on human blood and in vivo pathogenicity,
using a zebraﬁsh embryo model. In addition, a gene involved in tetrahydrofolate (THF)
biosynthesis, pabA, was identiﬁed as being required for virulence in vivo and was
unable to grow speciﬁcally on human blood. The relationship between human blood,
a folate-poor environment, and S. aureus pyrimidine salvage pathways was further
elucidated.
RESULTS
Screening of an S. aureus Tn library for growth defects on human blood. The
NTML was screened to deﬁne gene disruptions leading to alterations in growth and/or
hemolysis on agar containing human blood as the only nutrient source (see Materials
and Methods). The library was also screened on bovine serum agar and 5% (vol/vol)
sheep blood with a Columbia agar base as comparators, in order to determine traits
speciﬁc to human blood (data not shown). The transposon (Tn) insert for each strain
identiﬁed in the screen was transduced back into the parent strain (S. aureus JE2), and
transductants were rescreened in order to establish that the mutant phenotype was
associated with each Tn insertion. Fifteen transductants maintained the altered phe-
notype, and nine of these (the purB, purA, pabA, atl, murQ, araC, mecA, odhB, and lipA
transductants) were selected for further study (Table 1). The remaining six strains had
transposon disruptions in genes expected to produce an altered phenotype when
grown on human blood agar (agrA, agrB, agrC, hla, saeR, and saeS), conﬁrming the
ability of the screen to identify speciﬁc phenotypes.
Phenotypic characterization of growth-defective mutants in vivo. In order to
deﬁne genes for further study, the pathogenicity of the nine transduced strains in the
JE2 background was assessed using the zebraﬁsh embryo model of systemic S. aureus
infection (17). The atl, murQ, araC, mecA, odhB, and lipA transductants did not show
altered killing in this model (see Fig. S1a and b in the supplemental material). However,
three of the strains, harboring Tn inserts in the purA, purB, and pabA genes (referred to
here as JE2-purA, JE2-purB, and JE2-pabA), showed signiﬁcant attenuation in the
zebraﬁsh model (P  0.0001) (Fig. 1a). To conﬁrm that the reduced pathogenicity was
not strain speciﬁc, Tn inserts containing the purA, purB, and pabA genes were trans-
duced into another strain background, S. aureus SH1000. These strains (referred to here
as SH-purA, SH-purB, and SH-pabA) also showed signiﬁcant attenuation in the zebraﬁsh
embryo model (P  0.0001) (Fig. 1b). In vivo growth analysis demonstrated that
SH-purA and SH-purB were unable to replicate within zebraﬁsh embryos, and the
numbers of bacteria recovered were lower than the inoculated dose (Fig. 1c and d). This
is in stark contrast to the bacterial kinetics observed when the parental S. aureus strain
is injected at the same dose as that published previously (Fig. S1c) (17). SH-pabA
retained limited capacity to replicate and to cause host death in the zebraﬁsh model
(Fig. 1e). Using a knockdown approach to deplete zebraﬁsh myeloid cells (morpholino-
mediated pu.1 knockdown), SH-pabA was restored to a level of virulence similar to that
of the parental strain, but with a slight temporal delay (Fig. 1f). By 20 h postinfection
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(hpi), all embryos injected with the parent strain, and 80% of SH-pabA-injected em-
bryos, had succumbed. The remaining SH-pabA-injected embryos died over the follow-
ing 24 h. In myeloid cell-depleted zebraﬁsh, SH-purA and SH-purB caused the death of
approximately two-thirds of subjects injected, signiﬁcantly less than the parent strain
(P  0.0001). The pu.1 knockdown approach causes a temporary delay in phagocytic
cell development, and as expected, no further host death was observed after 40 h, a
time point at which phagocyte production would recover (18, 19).
Purine biosynthesis is required for growth in blood. Analysis of the purA and
purB genes (20, 21) demonstrated that purA and purB code for enzymes in the purine
biosynthesis pathways (adenylosuccinate synthase and adenylosuccinate lyase, respec-
tively) (see Fig. S2 in the supplemental material). In vitro, JE2-purA and JE2-purB showed
reduced growth on human blood and bovine serum agar plates but growth similar to
that of the parent strain on 5% (vol/vol) sheep blood, which contained a rich nutrient
base (data not shown). Growth assays of JE2-purA and JE2-purB were also conducted in
liquid media (brain heart infusion [BHI], bovine serum, or human serum) (Fig. 2a to c).
Growth was comparable to that of the parent only in the nutrient-rich BHI medium,
matching that seen in the initial NTML screen. This ﬁnding suggested that the reduced-
growth phenotype was due to a requirement for a nutrient not readily available in
human blood or in human or bovine serum. Analysis of the purine biosynthesis
pathway suggested that both strains should require adenine for growth, while in
addition to adenine, JE2-purB should also require guanine (or inosine). Chemically
deﬁned medium (CDM) analysis conﬁrmed that the growth of JE2-purA was dependent
on the presence of adenine, while the growth of JE2-purB was dependent on adenine
and guanine (Table 2; Fig. 2d). The addition of 20 g ml1 adenine and 20 g ml1
inosine restored the growth of each pur mutant, to levels similar to that obtained for
the parent strain (data not shown). Biochemical complementation of the purA and purB
mutants was not successful in the zebraﬁsh infection model, likely due to poor diffusion
of nucleobases into zebraﬁsh embryos (data not shown). The importance of purine
biosynthesis pathway enzymes in disease has been well characterized (22, 23).
pabA is required for virulence in the murine sepsis model and for growth in
human blood. In a mouse sepsis model, mice injected with S. aureus SH-pabA (4  107
FIG 1 In vivo characterization of S. aureus strains in the zebraﬁsh embryo model of infection with reduced growth in human blood in vitro. (a) Survival curves
of ﬁsh injected with wild-type S. aureus JE2 or with JE2-purA, JE2-purB, or JE2-pabA (1,500 CFU each). (b) Survival curves of ﬁsh injected with wild-type S. aureus
SH1000 (SH) or with SH1000 purA, SH1000 purB, or SH1000 pabA (1,500 CFU each). (c to e) Growth of S. aureus mutants within embryos after injection with
1,500 CFU of SH1000 purA (c), SH1000 purB (d), or SH1000 pabA (e). Open circles, live embryos; ﬁlled circles, dead embryos. (f) Survival curves of pu.1 knockdown
ﬁsh injected with wild-type S. aureus SH1000, SH1000 purA, SH1000 purB, or SH1000 pabA (1,500 CFU).
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CFU) lost signiﬁcantly less weight than those receiving the parent strain (2  107 CFU)
(Fig. 3a). Bacterial numbers were also signiﬁcantly lower in kidneys harvested from mice
injected with SH-pabA (Fig. 3b) (P  0.01).
The pabA Tn mutant was found to have a unique growth phenotype in the initial
screen. Growth was highly reduced on 30% (vol/vol) human blood but only slightly
reduced on 30% (vol/vol) rabbit blood (Table 1). However, the pabA mutant grew well
on both sheep and horse blood agar (30% [vol/vol]), demonstrating that the phenotype
was species speciﬁc (data not shown). In addition, the pabAmutant demonstrated good
growth on 50% (vol/vol) human serum or plasma agar (see Fig. S3 in the supplemental
material). To ascertain if the amount of human plasma in 30% (vol/vol) whole blood
agar was too small to support growth, the pabA mutant was compared to the parent
FIG 2 The S. aureus purA and purB mutants require exogenous purines for growth. (a to c) Strains were grown in BHI (a), bovine serum (b), or human serum
(c). Data are from three independent repeats; error bars represent standard errors. Circles, JE2; squares, JE2-purB; triangles, JE2-purA. (d) Growth of strains on
CDM agar plates with or without adenine (20 g ml1) and guanine (20 g ml1) after 24 h of aerobic incubation at 37°C.
TABLE 2 Growth analysis of JE2-purA and JE2-purB on solid media in the presence or
absence of adenine and guanine
Strain
Growtha on chemically deﬁned medium
With adenine
and guanineb
Without adenine
or guanine
With adenine,
without guanine
Without adenine,
with guanine
JE2    
purB mutant    
purA mutant    
a, growth; , no growth.
bThe concentration of adenine or guanine, when present, was 20 g ml1.
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strain on agar in which the plasma concentration was increased up to 50% (vol/vol). At
the lower concentrations of 10% (vol/vol) and 15% (vol/vol) (15% being the approxi-
mate concentration of plasma in 30% [vol/vol] blood agar), the growth of the pabA
mutant was poor but comparable to that of JE2. Therefore, the reduced growth of the
FIG 3 The pabABC operon is required for pathogenesis. (a and b) Female BALB/c mice (n  10) were injected i.v.
with 2  107 CFU S. aureus SH1000 (SH) or 4  107 CFU S. aureus SH1000 pabA (SH-pabA). Weight loss (a) and CFU
counts in the kidneys (b) were measured after 3 days. (c) Survival curves of ﬁsh injected with S. aureus SH1000
(1,500 CFU) or S. aureus SH1000 pabB. (d) Survival curves of ﬁsh injected with S. aureus SH1000 (1,500 CFU) or S.
aureus SH1000 pabC. (e) Growth of the parent strain (JE2), the pabA mutant, the genetically complemented pabA
strain (with pJC002 integrated) (strain JC006), or a control integrated strain (with the empty pKASBAR plasmid in
the pabA mutant) (strain JC007) on unsupplemented human blood agar (30%, vol/vol). Plates were incubated
aerobically at 37°C for 48 h. (f) Survival curves of ﬁsh injected with 1,500 CFU of S. aureus SH1000, S. aureus SH1000
pabA, S. aureus SH1000 pabA plus the pabABC operon (with pJC002 integrated) (strain JC010), or S. aureus SH1000
pabA with an empty plasmid only (pKASBAR) (strain JC011). (g) Survival curves of ﬁsh injected with 1,500 CFU of
S. aureus SH1000 or S. aureus SH1000 pabA followed by immediate immersion in either unsupplemented E3
medium (red) or E3 medium supplemented with 7 g ml1 PABA (black). Uninjected ﬁsh were included as controls
under each condition.
Connolly et al. Infection and Immunity
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pabA mutant on human blood was not a result of lower plasma levels in human blood
agar (data not shown).
PabA is an enzyme required for tetrahydrofolate (THF) synthesis (para-aminobenzoate
synthetase component II) (20), and pabA is found in an operon with pabB and pabC, which
is responsible for the synthesis of the folate pathway intermediate 4-aminobenzoic acid
(para-aminobenzoic acid [PABA]) (20). Strains from the NTML harboring a Tn disrupting
pabB or pabC were transduced into the SH1000 background and were also found to be
attenuated in the zebraﬁsh infection model (Fig. 3c and d) (P  0.001). Genetic
complementation of the pab operon restored JE2-pabA growth on human blood (Fig.
3e) and SH-pabA virulence in the zebraﬁsh model (Fig. 3f).
Reduced growth on human blood could be due to a lack of nutrients that are
required by a strain lacking THF. The end product of the folate pathway, THF, acts as
a single-carbon donor/acceptor in glycine/serine interconversion, vitamin B5 synthesis,
methionine synthesis, purine synthesis, N-formylmethionine-tRNA charging, glycine
cleavage, and dTMP synthesis (see Fig. S4 in the supplemental material). To further
characterize pabA, different media were used to interrogate the mechanism underpin-
ning the lack of growth on human blood. With liquid culture, the growth of the pabA
mutant was comparable to that of the wild type in BHI, bovine serum, and human
serum (data not shown), suggesting that the reduced-growth phenotype was speciﬁc
to blood. When CDM lacking purines, serine, and glycine was used as the base, only the
addition of purines, serine, and glycine together could restore the growth yield of the
mutant to parental levels (as measured by the maximum optical density at 600 nm
[OD600] reached) (data not shown). Biochemical complementation with the same
supplements did not restore the growth of the pabA mutant on human blood, nor did
the addition of folic acid. However, the addition of PABA fully complemented growth
(see Fig. S5a in the supplemental material), as would be expected based on similar work
done with Lactococcus lactis (24). Immersion of SH-pabA-injected zebraﬁsh embryos in
E3 medium containing PABA restored virulence in vivo (Fig. 3g) (P  0.0001).
Pyrimidine salvage pathways are required to bypass pabA. dTMP is synthesized
via a THF-dependent route, or via an alternative nucleotide salvage pathway requiring
thymine or thymidine (Fig. 4a). A combination of glycine, serine, and purines could not
restore the growth of the pabA mutant on human blood; however, the addition of
pyrimidines (thymine) supported growth to the extent of the parent strain, JE2 (Fig. S5a
in the supplemental material). The crucial role of pyrimidines in bacterial survival under
conditions of folate deprivation has been reported previously (25, 26). Neither pyrim-
idines nor folic acid could restore the pathogenicity of the pabAmutant in the zebraﬁsh
embryo model (data not shown).
Double mutants defective in pabA and one of the pyrimidine nucleotide salvage
pathway genes—pdp, tdk, or the thymidine transporter gene, nupC—were constructed
in order to assess the roles of these genes in pabA growth. The growth of all three
double mutants was reduced on human blood but could be complemented with PABA
(Fig. S5b in the supplemental material). The addition of thymine or thymidine to blood
could complement all the mutants except for the pabA tdk double mutant. This
highlighted the fact that pyrimidine salvage pathways are required to bypass the deﬁcit
of pabA. If an inhibitory factor in blood was responsible for preventing the growth of
the pabAmutant, Tdk was the likely target. Unexpectedly, the pabA pdp double mutant
was complemented by thymine, and the pabA nupC mutant was complemented by
thymidine. This suggests that thymine can be converted to thymidine independently of
Pdp and that an alternative thymidine transporter to NupC is available in S. aureus. Two
remaining putative pyrimidine transporters have been identiﬁed in S. aureus and have
not yet been investigated (27).
Investigating a nucleotide salvage pathway inhibitory component in human
blood. The nucleotide salvage pathway appears to provide enough dTMP (later
converted to dTTP) for the DNA synthesis and growth of the pabA mutant on human
plasma or serum, but not on human blood, unless thymine or thymidine is added. This
Nucleotide Salvage Required for S. aureus Disease Infection and Immunity
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suggested that either a factor in whole blood competitively inhibits the nucleotide
salvage pathway enzymes or growth on human blood leads to an increased require-
ment for dTMP, which cannot be met without increasing the thymine or thymidine
concentration (Fig. 4a). To hone in on an inhibitory factor, different components of
blood were assessed for their abilities to replicate the poor-growth phenotype of the
pabA mutant seen on whole human blood. The growth of JE2-pabA was comparable to
that of JE2 on platelet-rich plasma (PRP) and on PRP that had been vortexed to disrupt
platelets (data not shown). Similarly, the growth of the parent strain and that of the
mutant were equivalent when white blood cells (WBCs), either intact or lysed, were
added to platelet-poor plasma (PPP). Vortexing of whole human blood followed by
centrifugation produces red, rather than straw-colored, plasma, indicating red blood
cell (RBC) lysis. Plasma from vortexed blood was mixed with PPP to give a 9:1 ratio of
nonvortexed to vortexed plasma, decreasing incrementally to a ratio of 1:9. At the
lowest ratio of nonvortexed to vortexed plasma, the growth of JE2-pabA was greatly
reduced (Fig. 4b). This suggested that there is a potent inhibitor of the growth of the
pabA mutant in the RBC component of human blood.
Hemoglobin or heme was deemed a likely candidate for the inhibitory factor.
Hemoglobin, a complex of four heme groups, is the most abundant hemoprotein in
humans. Heme is an iron-containing ring structure, and usage of heme as an iron
source can be toxic to bacteria due to its active redox potential (28). Although the
underlying mechanisms are not fully understood, it has been reported that heme-
induced monooxygenase-like activity can cause direct DNA damage (28, 29). In S.
FIG 4 Folate biosynthesis pathway and effect of lysed RBCs on the growth of S. aureus pabA. (a) The folate biosynthesis and pyrimidine nucleotide salvage
pathways (20, 21). Possible hypotheses for poor pabA growth on human blood are shown: either S. aureus Tdk is the target of competitive inhibition by human
blood (frame 1) or increased dTMP demand necessitates supplemental thymidine in S. aureus (frame 2). (b) Growth of S. aureus JE2 or JE2-pabA on nonvortexed
human PPP or with a decreasing ratio of vortexed to nonvortexed agar. Plates were incubated aerobically at 37°C for 48 h.
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aureus, heme is extracted from hemoglobin and is transported into the cell by the
iron-regulated surface determinant (Isd) system (30). Toxicity induced by the liberation
of iron from heme by S. aureus is reduced by the two-component heme-regulated
transporter (hrtAB). Heme is also transported into S. aureus by the ABC transporter
HtsABC, which requires the extraction of heme from hemoglobin by the Isd system (30).
Both transport systems are upregulated under low Fe conditions by alleviation of the
negative regulator Fur. However, supplementation of human blood agar with an
alternative Fe source (ammonium ferrous sulfate) did not support the growth of
JE2-pabA on human blood (data not shown). In addition, lyophilized bovine hemin,
bovine hemoglobin, and human hemoglobin failed to prevent the growth of the pabA
mutant on plasma (data not shown).
S. aureus growth in human blood requires increased levels of pyrimidines.
Rather than an inhibitory factor in blood preventing the growth of the pabA mutant, it
is possible that human blood leads to an increased requirement for dTMP, which
cannot be met in a folate-deﬁcient mutant reliant solely on the pyrimidine salvage
pathway (Fig. 4a). Thymidylate synthase (encoded by thyA) is highly conserved, requir-
ing THF as a cofactor for the conversion of dUMP to dTMP, an essential step in DNA
synthesis. To maintain viability, thyA mutants can utilize extracellular thymidine via
pyrimidine salvage pathways (31) and thus cannot grow in vitro on media lacking
pyrimidines, such as Mueller-Hinton (MH) agar or human blood (27). To determine if
human blood increases the demand for pyrimidines, a minimal permissive concentra-
tion of thymidine to allow thyA mutant growth (500 ng ml1) was added to MH agar
(Fig. 5a). As the concentration of added human blood increased, ranging from 1 to 50%
(vol/vol), the growth of the thyA mutant was increasingly inhibited, suggesting that, as
with the pabAmutant, pyrimidine requirements are elevated by human blood. This was
further conﬁrmed by the addition of a higher concentration of thymidine (400 g
ml1), which allowed biochemical complementation of thyA (Fig. 5b).
In the host environment, when innate immune cells encounter bacteria, reactive
oxygen species (ROS), such as superoxide and nitric oxide, are generated (32). Bacteria
have developed sophisticated mechanisms to resist such oxidative stress. Although
heme acquisition is a necessity for S. aureus survival in vivo, we hypothesized that heme
causes oxidative stress on bacteria, increasing dTTP requirements for DNA repair, and
that the pabA mutant would be less able to compensate than the parent strain. To test
this hypothesis, the pabA mutation was transduced into a strain unable to acquire
heme due to disrupted Isd and heme transport systems, LS1 ΔisdE ΔhtsA (33). The triple
mutant (LS1 ΔisdE ΔhtsA pabA) was inoculated onto human blood agar in order to
determine whether the removal of potential heme toxicity would restore the growth of
the pabA mutant. No growth was observed for the pabA or ΔisdE ΔhtsA pabA strain on
unsupplemented blood agar, but both strains displayed good growth in the presence
of exogenous pyrimidines (data not shown). However, it has been demonstrated that
in the absence of functional heme transport and Isd systems, S. aureus can still acquire
heme, by a third, as yet unknown heme transport mechanism (33).
In the presence of sulfonamide antibiotics, nucleotide salvage pathways are
required for S. aureus growth in blood. The use of folate-antagonistic sulfonamide
antibiotics, such as trimethoprim, against S. aureus leads to the loss of THF synthesis
and, like the pabA mutation, a dependence on the pyrimidine nucleotide salvage
pathway for dTMP synthesis. The activity of this class of antibiotics can be reversed by
providing enough thymidine to bypass the requirement for the THF-dependent dTMP
synthesis pathway (34). The reversal of trimethoprim activity against JE2, JE2-pabA, and
JE2-tdk by pyrimidine was assessed by growth on human, sheep, or horse blood agar.
On human blood, thymidine reversed the activity of trimethoprim against JE2, and
JE2-pabA growth was restored in the presence of thymidine; however, trimethoprim
was active against JE2-tdk in the presence or absence of thymidine (Table 3). Similar
results were obtained on horse blood. On sheep blood, trimethoprim was inactive
against JE2 and JE2-pabA, likely due to a higher pyrimidine concentration in sheep
blood (35), demonstrating that the JE2-pabA phenotype on human blood may also be
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due to differences in the pyrimidine content of blood. As with human and horse blood,
JE2-tdk was inhibited by trimethoprim on sheep blood, and the addition of thymidine
could not reverse this inhibition, since the nucleotide salvage pathways are prohibited.
DISCUSSION
In order to identify novel pathogenicity determinants, an ordered library of trans-
poson mutants was screened for gene disruptions causing growth and hemolysis
defects on agar containing human blood as the only nutrient source. This screen
identiﬁed purA, purB, and pabA as required for growth on human blood. The purA and
purB genes are part of the de novo biosynthetic pathway for purines, and pabA is
FIG 5 Increased concentrations of thymidine are required for S. aureus growth on human blood. (a) Growth
of S. aureus SH-thyA on MH agar. The medium either was left unsupplemented (top left) or contained a
permissive concentration of thymidine (500 ng ml1). Increasing concentrations of human blood, ranging
from 1 to 50% (vol/vol), were added to the MH agar base, which contained thymidine (500 ng ml1). Plates
were incubated aerobically at 37°C for 24 h. (b) At concentrations of human blood causing reduced
S. aureus SH-thyA growth, biochemical complementation was achieved by the addition of 400 g ml1
thymidine. Plates were incubated aerobically at 37°C for 24 h.
TABLE 3 Trimethoprim MICs for the S. aureus parent strain, JE2-pabA, and JE2-tdk on
various media
Strain
Trimethoprim MIC (mg/liter) for the indicated strain on the following
mediuma:
BHI Human blood Sheep blood Horse blood
T T T T T T T T
Parent 1 32 0.75 32 32 32 1 32
pabA mutant 1 32 32 32 32 0.002 32
tdk mutant 0.25 0.25 0.75 0.75 0.5 0.5 1 1
aT, no exogenous thymidine added, T, thymidine added at 400 g ml1.
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involved in folate synthesis. All three mutations were found to lead to signiﬁcant
attenuation in the zebraﬁsh model of systemic infection, conﬁrming the important role
of these genes in pathogenesis.
In a study using a microarray-based system to detail the nonessential genes in-
volved in the growth of Escherichia coli, Salmonella enterica, and Bacillus anthracis in
human serum, the majority of mutants identiﬁed were involved in purine or pyrimidine
biosynthesis (10). This suggests a scarcity of nucleotides in vivo, which bacteria coun-
teract by being equipped with energetically costly metabolic pathways permitting de
novo synthesis. Similarly, in our study, the ability of purine biosynthesis mutants to
grow in nutrient-rich media suggested that purA and purB mutants require nutrients
not readily available in human serum, whole blood, or the live zebraﬁsh.
The reduced growth of S. aureus pabA in vitro was intriguing, because it was speciﬁc
to human blood; normal growth was seen on blood components (serum, plasma), horse
blood, and sheep blood. PabA is required for the production of PABA, an essential
intermediate in the synthesis of THF. A pabB mutant of Streptococcus pneumoniae has
been used as an attenuated strain for vaccine research, highlighting the importance of
this pathway in the development of prophylactic strategies (36). The use of liquid CDM
and solid CDM agar showed that purines, glycine, and serine were required for growth
by the pabA mutant in excess of the amounts required by the parental strain. However,
when assessed on human blood agar, growth inhibition could not be rescued with any
compound except pyrimidines, suggesting that all other factors necessary to bypass
the lack of THF are present in serum, plasma, and whole blood. The concept of
“thymineless death” has been introduced previously and demonstrates the fundamen-
tal importance of pyrimidines in bacterial survival, over and above the other down-
stream effectors of THF (25). The addition of thymidine to human blood permitted the
growth of the pabA mutant (Fig. S5a in the supplemental material). Human blood is
known to have a lower thymidine content than the blood of other animals (35).
However, the growth of the mutant on other thymidine-poor media (e.g., CDM, horse
blood) suggested that thymidine deﬁciency per se was not solely responsible for the
growth phenotype.
In the absence of THF-dependent thyA activity, pyrimidine salvage pathways are
essential for the conversion of thymidine to dTMP (via Tdk), which is necessary for DNA
replication. Both the pabA and the thyA mutant rely on these salvage pathways to
provide a permissive amount of thymidine and, therefore, dTTP, allowing them to
remain viable. It is difﬁcult to tease apart exactly how human blood subverts this
process, and we hypothesized that Tdk was the target of competitive inhibition in the
pabA mutant, given that supplemental thymidine restored the growth of the pabA
mutant, and a genetic knockout of pabA and tdk eliminated this biochemical comple-
mentation. Double knockouts of pabA with the gene responsible for the conversion of
thymine to thymidine (pabA pdp) or with a pyrimidine transporter gene (pabA nupC)
had no effect on biochemical complementation. Furthermore, the growth of the pabA
mutant was reduced on human plasma supplemented with lysed RBC products. Since
excess heme is toxic to S. aureus (28), heme and related molecules were ruled out as
Tdk inhibitory factors. Tdk is a zinc-requiring enzyme that is purported to be required
for transcriptional regulation (37). Zinc sequestration by human blood and other
potential inhibitory factors should be investigated in future work (38).
Although the exact mechanism has yet to be elucidated, it is clear that human
blood, or a component thereof, leads to an increased demand for dTMP, which cannot
be met in a THF-deﬁcient mutant; hence, exogenous thymidine or thymine is necessary
to support the growth of the mutant speciﬁcally on human blood.
Finally, little is known about the clinical prevalence or relevance of pabA mutations.
Trimethoprim is used in the control of S. aureus infections, and long-standing treatment
can lead to failure due to the development of antibiotic resistance (39). In this context,
thyAmutations are usually observed in the resistant subpopulation, and such mutations
cause the formation of thymidine-dependent small-colony variants (SCVs), which rely
on pyrimidine salvage pathways (via Pdp and Tdk) (40). However, sulfonamide antibi-
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otics remain bactericidal unless a thymidine-rich environment exists, such as damaged
host tissues, which allow S. aureus to utilize pyrimidine salvage pathways and thus
survive (41). The work presented here suggests that the activity of sulfonamide drugs
results from the inhibition of THF coupled with reduced activity of the pyrimidine
salvage pathways and/or an increased demand for dTMP imparted by human blood.
The identiﬁcation of metabolic pathways important for host-pathogen interactions
provides novel avenues to be explored in the effort to combat antibiotic-resistant
pathogens.
MATERIALS AND METHODS
Ethics statement. Zebraﬁsh embryos less than 5 days postfertilization (dpf) are not protected under
the Animals (Scientiﬁc Procedures) Act 1986, but all zebraﬁsh work was carried out according to the
details set out in Project License PPL 40/3574. Murine work was carried out according to UK law in the
Animals (Scientiﬁc Procedures) Act 1986, under Project License PPL 40/3699. Human blood was obtained
from healthy volunteers in compliance with the guidelines of the South Shefﬁeld Research Ethics
Committee (STH13927).
Bacterial strains, plasmids, and growth conditions. The Nebraska transposon mutagenesis library
(11) was acquired from the Network on Antimicrobial Resistance in S. aureus (NARSA) strain repository,
now available from BEI Resources (www.beiresources.org/), and was used for screening experiments.
Originally in the USA300 LAC JE2 background, mutations were transduced back into JE2 or SH1000 as
required. All other strains, and the plasmids used in this study, are listed in Table 4. S. aureus strains were
routinely grown in brain heart infusion (BHI) medium at 37°C with aeration at 250 rpm, unless otherwise
stated. Mueller-Hinton agar (Oxoid) was used as a thymidine-poor medium where stated. E. coli strains
were grown in Luria-Bertani medium at 37°C with aeration at 250 rpm. Agar at 1.5% (wt/vol) was added
for solid media. Antibiotics were added as required. For MIC determination, a bacterial colony was
inoculated into 2 ml sterile distilled water (dH2O) and was spread onto an agar plate using a sterile swab
(Oxoid). Trimethoprim Etests (bioMérieux) were applied to the solid medium surface using tweezers, and
incubation was carried out overnight at 37°C.
The chemically deﬁned medium used in this study has been described previously (42). The following
components were dissolved in 1 liter of H2O: Na2HPO4·2H2O, 7 g; KH2PO4, 3 g; L-aspartic acid, 0.15 g;
L-alanine, 0.1 g; L-arginine, 0.1 g; L-cysteine, 0.05 g; glycine, 0.1 g; L-glutamic acid, 0.15 g; L-histidine, 0.1
g; L-isoleucine, 0.15 g; L-lysine, 0.1 g; L-leucine, 0.15 g; L-methionine, 0.1 g; L-phenylalanine, 0.1 g; L-proline,
0.15 g; L-serine, 0.1 g; L-threonine, 0.15 g; L-tryptophan, 0.1 g; L-tyrosine, 0.1 g; L-valine, 0.15 g; biotin, 0.02
g; pyridoxal HCl, 0.8 g; nicotinic acid, 0.4 g; pyridoxamine di-HCl, 0.8 g; D-pantothenic acid, 0.4 g;
riboﬂavin, 0.4 g; thiamine HCl, 0.4 g; adenine sulfate, 0.02 g; guanine HCl, 0.02 g; CaCl2·6H2O, 0.01 g;
(NH4)2Fe(SO4)2·6H2O, 0.006 g; glucose, 10 g; MgSO4·7H2O, 0.5g. Inosine was used at 20 g/ml.
Human, or other animal, blood or blood components were added to agar at various concentrations,
as required. Venous blood was collected from healthy volunteers following informed consent. For plasma
preparation, blood was centrifuged at 270  g for 20 min in 50-ml Falcon tubes. The upper, platelet-rich
TABLE 4 Strains and plasmids used in this study
Strain or plasmid Relevant genotype/markers Source or reference
Strains
S. aureus strains
SH1000 Functional rsbU derivative of 8325-4 51
RN4220 Restriction-negative, modiﬁcation-positive strain 52
USA300 JE2 USA300 LAC strain cured of plasmids p01 and p03 11
SJF4669 SH-pabA::spc pdp::ery This study
SJF4670 SH-pabA::spc nupC::ery This study
SJF4671 SH-thyA::ery 27
SJF4678 SH-pabA::spc tdk::ery This study
JC006 JE2-pabA, pJC002 inserted at lipase; pabA Eryr Linr Tetr This study
JC007 JE2-pabA, pKASBAR inserted at lipase; Eryr Linr Tetr This study
JC010 SH-pabA, pJC002 inserted at lipase; pabA Eryr Linr Tetr This study
JC011 SH-pabA, pKASBAR inserted at lipase; Eryr Linr Tetr This study
LS1 Spontaneous murine arthritis isolate 53
LS1 ΔisdE ΔhtsA LS1 derivative; ΔisdE ΔhtsA 33
E. coli TOP10 F mcrA Δ(mrr-hsdRMS-mcrBC) 80 lacZΔM15 ΔlacX74 recA1 deoR araD139 Δ(ara-leu)7697
galK rpsL (Strr) endA1 nupG
Invitrogen
Plasmids
pKASBAR Hybrid vector of pCL84 and pUC18 for integration into S. aureus lipase gene (geh), attP;
Tetr (S. aureus); Specr (E. coli)
46
pJC002 pKASBAR containing the pab operon, with pabA, pabB, and pabC, and upstream control
elements; Tetr
This study
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phase was collected and was either used directly as platelet-rich plasma (PRP) or centrifuged again at
1,155  g for 30 min to yield platelet-poor plasma (PPP). Plasma was stored at 20°C. Animal blood and
blood products were purchased from Thermo Scientiﬁc or Sigma and were stored at 4°C. Bovine hemin
or hemoglobin, human hemoglobin, thymine, thymidine, glycine, serine, PABA, or folic acid was added
to media as and when required.
Genetic manipulation. Electroporation was used to transform S. aureus RN4220 and E. coli using
previously published methods (43, 44). All S. aureus transduction experiments were carried out with 11
as described previously (45).
For genetic complementation of SH-pabA and JE2-pabA, Phusion polymerase (NEB) was used to
amplify the pab operon from S. aureus SH1000 genomic DNA, using primers containing appropriate
restriction sites (forward, ATAATAGGGCCCATTGTA-CTGTCTTGACCACCACT; reverse, ATAATACTCGAGATA
CGTATACAAGAATTAA-CAACAGCA). The PCR product was inserted into pKASBAR (46), a plasmid encod-
ing an attP site. Using this attP site, bacteriophage DNA can integrate into the S. aureus genome at the
attB site, in the presence of an integrase (47). The attB site is located at the glycerol ester hydrolase (geh)
gene, so integration can be veriﬁed by loss of lipase activity. For such genetic manipulation, the integrase
is provided by an additional helper plasmid, pYL112Δ19, propagated in the S. aureus recipient strain,
RN4220. The insert was then transduced from RN4220 into pabA and control strains.
To prepare double mutants within Tn insertions, the “toolkit” for switching antibiotic resistance
within NTML strains was used as published previously (48). Tn inserts in pdp, nupC, and tdk genes, with
alternate antibiotic resistance markers, were transduced into the pabA mutant as listed in Table 4.
Strains LS1 and LS1 ΔisdE ΔhtsA were kindly provided by Sean Nair (University College London). pabA
was transduced into both strains, and successful transductants were conﬁrmed by PCR.
Transposon library screen. The NTML was grown for 18 h at 37°C in 96-well microtiter dishes. Using
a 96-pin replicator (Boekel Industries), the contents of each well were transferred to BHI agar, BHI agar
plus erythromycin (10 g/ml) and lincomycin (25 g/ml), 30% (vol/vol) human blood agar, 50% (vol/vol)
bovine serum agar, and 5% (vol/vol) sheep blood, plus Columbia agar base in rectangular OmniTray
plates (Nunc). Human blood and bovine serum plates were incubated for 48 h at 37°C; all other plates
were incubated for 18 h at 37°C, with an additional 4 h at 4°C for sheep blood plates, to ensure efﬁcient
hemolysis. Phenotypes were determined by comparison of each spot (colony size and hemolysis zone)
to the surrounding spots on the plate.
Zebraﬁsh model. Zebraﬁsh embryos, strain London wild type (LWT), were maintained in E3 medium
at 28°C by following standard protocols (17). Embryos were bred in the aquarium facilities at the
University of Shefﬁeld. Microinjection of embryos was performed as described previously (17). Individual
infected embryos were kept in 100 l E3 medium, and survival was assessed over 90 h. For in vivo
complementation experiments, compounds were dissolved in E3 medium and were buffered to a pH of
6.5 to 7.5. Immediately following injections, embryos were placed in appropriate compound solutions.
Further compound solution was added in the embryo washing step. Ninety-six-well microtiter plates
were placed in a plastic box, with damp paper, to reduce evaporation during incubation.
pu.1-antisense morpholino-modiﬁed oligonucleotides (49) were injected into zebraﬁsh embryos
using the method described previously (17). Bacteria were recovered from infected embryos at 12-h
intervals. Individual embryos were transferred to microcentrifuge tubes and were homogenized using a
PreCellys 24-Dual homogenizer (Peqlab). Bacterial numbers were then determined by serial dilution in
phosphate-buffered saline (PBS) and plating onto BHI agar.
Murine infection model. Female BALB/c mice were purchased from Charles River Laboratories
(Margate, UK) and were maintained by standard husbandry techniques at the University of Shefﬁeld
(Biological Services). Bacteria were washed in endotoxin-free PBS (Sigma), and 100 l (2 107 to 4 107
CFU) was injected intravenously (i.v.) into the tail vein. Serial dilutions of culture were prepared to
conﬁrm the injection CFU. Mice were monitored and were sacriﬁced at 72 hpi. Mouse organs were
individually homogenized in PBS and, after serial dilution, plated onto BHI agar supplemented with
antibiotics as needed for bacterial enumeration.
Statistical analysis. Sample sizes were predetermined for mouse (n  10) and zebraﬁsh (n  20)
experiments based on previous experimental data (50). All zebraﬁsh experimental results are represen-
tative of 2 experiments unless otherwise stated. For zebraﬁsh embryo survival experiments, the Kaplan-
Meier method was employed. Survival curves were compared using the log rank (Mantel-Cox) test. For
bacterial count comparisons in murine experiments, the Mann-Whitney U test was used. Statistical
analysis was performed using Prism, version 6.0 (GraphPad), and a P value of 0.05 was considered
signiﬁcant.
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